Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably.

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he’s confirmed to lead the Department of Health and Human Services? And how do you pronounce Journavx?

New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), ...

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...

CRISPR, later this year, which will likely be a price catalyst and further support my long-term bullishness. FDA Approval Boosts Vertex Commercialization Plans Vertex Pharmaceuticals shares surged ...